Aarti Sevilimedu

Principal Research Scientist

Research area :

  • RNA mediated regulation of cellular processes in fission yeast, RNA aptamer technology and Rare disease models

Education & Training :

  • 2002 – 2008: Ph.D. in Biochemistry, Cell and Molecular Biology, Cornell University, Ithaca, NY, USA
  • 1998 – 2002 : Bachelor of Technology in Industrial Biotechnology, Center for Biotechnology, Anna University, Chennai, India.

Professional Experience :

  • 2009 – 2012:Postdoctoral Researcher at Harvard Medical School, Boston, MA.
  • 2013 – 2018: Senior Research Scientist at DRILS, Hyderabad, India.
  • 2018 –          : Principal Research Scientist and Research Coordinator, Rare Diseases program at DRILS, Hyderabad, India.

Research interests :

  • The central theme for research in Aarti’s lab is the RNA molecule. The work on RNA biology is divided into two independent but complementary areas: the first is to determine how and why the cell uses ncRNA to regulate cellular processes such as gene expression and silencing, and the second is to come up with novel ways to use synthetic RNA molecules, as a tool, a marker or a drug to alter cellular processes. In addition to this, Aarti’s laboratory is also involved in creation of Zebrafish models for rare diseases in order to explore fundamental biology as well as develop therapies.

Publications :

  • Medishetti R, Rani R, Kavati S, Mahilkar A, Akella V, Saxena U, Kulkarni P*, Sevilimedu A*. A DNAzyme based knockdown model for Fragile-X syndrome in zebrafish reveals a critical window for therapeutic intervention. J Pharmacol Toxicol Methods. 2020 Jan – Feb; 101:106656. doi: 10.1016/j.vascn.2019.106656. PMCID: 31734279
  • Kulkarni P, Sevilimedu A. The Known Unknowns: Missing Pieces in in vivo Models of Fragile X Syndrome. J Rare Dis Res Treat. (2020) 5(1): 1-9

Link to Google Scholar Page :